Sugi Predict

Sugi Predict / Compounds / SCHEMBL6867310

SCHEMBL6867310

SCHEMBL6867310

Cc1ccc(C)c(S(=O)(=O)N[C@H]2CC[C@@H](Nc3ccnc4cc(Cl)ccc34)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT5B Q4FZB7 2/20 0.58
▸ KMT5C Q86Y97 2/20 0.58
▸ NSD2 O96028 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ CYP2D6 P10635 2/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ BRD4 O60885 2/20 0.43
▸ BRD2 P25440 2/20 0.43
▸ BRD3 Q15059 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6867309 1.00 KMT5B (0.58) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6869219 0.90 KMT5B (0.56) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6869221 0.90 KMT5B (0.56) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6872893 0.90 L3MBTL1 (0.60) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6872896 0.90 L3MBTL1 (0.60) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6870292 0.88 KMT5B (0.61) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6870299 0.88 KMT5B (0.61) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6861655 0.87 KMT5B (0.53) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6861658 0.87 KMT5B (0.53) KMT5BKMT5CNSD2KDM4EKMT2A
SCHEMBL6866045 0.85 KMT5B (0.63) KMT5BKMT5CNSD2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 — — US claimed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 — — US claimed
WO-2003070244-A1 ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES ABBOTT LABORATORIES (US) 2003-08-28 — — WO claimed
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 — — US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R KMT5B 1214/4885KMT5C 1285/4885NSD2 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.